麗珠醫藥(01513.HK)擬4月12日舉辦2021年網上業績説明會
格隆匯4月6日丨麗珠醫藥(01513.HK)公吿,為了加強與公司投資者,特別是中小投資者的溝通和交流,進一步瞭解公司2021年度經營業績及未來發展情況,公司定於2022年4月12日(星期二)15:00至17:00在全景網舉辦公司2021年年度報吿網上業績説明會,説明會將採用網絡遠程的方式舉行,投資者可登陸全景網“投資者關係互動平台”(http://ir.p5w.net)參與説明會。説明會是深圳證券交易所繫列業績説明“專精特新新勢力主題”的特定活動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.